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Abstract We examined the role of the mitogen-activated
protein (MAP) kinase pathway in tissue inhibitor of metallopro-
teinases-1 (TIMP-1)-mediated cellular effects in a human
erythroleukemic cell line UT-7. We show that TIMP-1 induced
both UT-7 cell erythroid differentiation and proliferation and
tyrosine phosphorylation of many intracellular proteins. Using a
panel of phosphospecific antibodies, we also demonstrate that
phosphorylation of the p38 and c-Jun N-terminal kinases is
increased by TIMP-1 whereas phosphorylation of extracellular
signal-regulated kinase 1/2 is not induced. Moreover, inhibition
of the p38 activity by SB203580 significantly reduces erythroid
differentiation induced by TIMP-1, suggesting that the p38
MAP kinase pathway is involved in TIMP-1-induced erythroid
differentiation. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
The extracellular matrix turnover is controlled by the bal-
ance between matrix metalloproteinases (MMPs) and tissue
inhibitors of metalloproteinases (TIMPs). TIMPs are secreted
proteins involved in the maintenance of tissue architecture.
Four members have been characterized in a variety of species
and designated TIMP-1, -2, -3 and -4. They possess 12 con-
served cysteine residues involved in disul¢de bonds and they
form non-covalent inhibitory complexes with MMPs [1]. Con-
trasting with their inhibitory activity, TIMP-1 and -2 have
been shown to exert mitogenic e¡ects in vitro in a wide range
of cells including ¢broblasts, chondrocytes, lymphoma cells
and several cancer cell lines [2,3]. TIMPs also possess ery-
throid potentiating activity (EPA) so modulating growth
and di¡erentiation of erythroid precursors and of the K562
erythroleukemia cell line [4,5]. These cell growth promoting
e¡ects seem to be a direct cellular e¡ect and could be medi-
ating by cell surface receptors [6]. Up to date little is known
about the signal transduction pathway induced by TIMPs. In
¢broblasts, TIMP-2 stimulates proliferation by directly acti-
vating adenylate cyclase so producing cyclic adenosine mono-
phosphate (cAMP) which then activates cAMP-dependent
protein kinase A [2]. In human osteosarcoma cell line MG-
63, TIMP-1 and -2 stimulate DNA synthesis mediated
through activation of mitogen-activated protein (MAP) ki-
nases [7].
In the present study, we report that the erythroid di¡er-
entiation induced by TIMP-1 is mediated through activation
of the p38 MAP kinase and c-Jun N-terminal kinases (JNK)
1/2 in the erythroleukemic cell line UT-7.
2. Materials and methods
2.1. Reagents
Human recombinant TIMP-1 and SB203580 were purchased from
Calbiochem. Human puri¢ed recombinant erythropoietin (Epo) (spe-
ci¢c activity of 120 000 U/mg) was purchased from Roche Molecular
Biochemicals. K-Minimal essential (K-MEM) and Iscove’s modi¢ed
Dulbecco’s media were purchased from Life Technologies, Inc.
Anti-p38 MAP kinase antibodies ((C-20)-G) were obtained from San-
ta Cruz Biotechnology, Inc. Anti-phospho-p38 MAP kinase, phospho-
JNK1/2 and phospho-p42p44 antibodies were obtained from New
England Biolabs. Anti-phosphotyrosine antibodies (4G10) were pur-
chased from Upstate Biotechnology, Inc. ECL substrate solution was
from Amersham Pharmacia Biotech. All others reagents were pur-
chased from Sigma Aldrich.
2.2. Cell culture and stimulation
UT-7 Epo-dependent cells were cloned from the human leukemic
cell line UT-7 [8]. These cells were able to grow in the presence of Epo
and express erythroid di¡erentiation markers [9]. UT-7 cells were
cultured in K-MEM containing 10% fetal calf serum, 2 mM L-gluta-
mine and 2 U/ml Epo. Before each experiment, cells were serum- and
Epo-deprived by incubation overnight in Iscove’s modi¢ed Dulbecco’s
medium supplemented with 0.2% deionized bovine serum albumin,
2 mM L-glutamine and 20 Wg/ml human holo-transferrin. To study
proliferation and erythroid di¡erentiation, cells were incubated for
48 h in the same medium with TIMP-1 at the speci¢ed concentrations.
Cell viability was determinated by trypan blue exclusion and hemo-
globin synthesis determinated by benzidine staining [10]. To study
stimulation and signal transduction, cells were incubated in Iscove’s
modi¢ed Dulbecco’s medium with di¡erent concentrations of TIMP-1
and stimulated for 0^30 min at 37‡C. Stimulation was stopped by
adding ice-cold phosphate-bu¡ered saline (PBS) containing 50 WM
Na2VO4.
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2.3. Whole cells extracts
Prior to stimulation, cell concentration was adjusted to 1U106 cells/
ml. After stimulation as described above, cells were washed twice in
PBS containing 50 WM Na2VO4. Cells were pelleted and solubilized by
adding 80 Wl 2U Laemmli bu¡er. Samples were boiled and analyzed
by 7.5% sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) and Western blotting.
2.4. Immunoprecipitation
After cell stimulation and washing as described above, cells
(10U106) were lysed for 15 min at 4‡C in lysis bu¡er containing
10 mM Tris^HCl, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 10%
Brij 98, 1 mM phenylmethylsulfonide £uoride (PMSF), 10 Wg/ml leu-
peptin, 10 Wg/ml aprotinin and 1 mM Na2VO4 pH 7.4. Insoluble
material was then removed by centrifugation (15 800Ug, 20 min)
and the supernatant was incubated with the speci¢c antibodies for
1 h at 4‡C. The mixture was then transferred to protein G-Sepharose
pellets and rocked for 1 h at 4‡C. The Sepharose beads were washed
once with lysis bu¡er containing 1% Brij 98 and four times with lysis
bu¡er containing 0.1% Brij 98 and 1 mM Na2VO4. Then, the Sephar-
ose beads were boiled in 1U Laemmli sample bu¡er, the proteins were
separated by SDS^PAGE and analyzed by Western blotting.
2.5. Western blotting
After SDS^PAGE, the proteins were transferred to a nitrocellulose
membrane. The membrane was blocked with 5% non-fat dry milk in
Tris-bu¡ered saline pH 7.5 containing 0.1% Tween 20 (TBST) for 2 h
at room temperature. The blot was then incubated with primary anti-
body overnight at 4‡C. After ¢ve washes with TBST, the blot was
incubated with horseradish peroxidase-conjugated secondary anti-
body. Immunoblotting was detected by adding ECL substrate solu-
tion and exposing to Kodak X-Omat ¢lm. When necessary, blot was
stripped by incubating the membrane for 30 min at 55‡C in 62.5 mM
Tris^HCl pH 6.7 containing 100 mM L-mercaptoethanol and 2%
SDS. The blot was then washed ¢ve times with 50 mM Tris^HCl
pH 7.5 containing 150 mM NaCl, 0.1% Tween 20 and reprobed as
described above.
2.6. Bacterial expression of GST-fusion protein ATF2
Glutathione S-transferase (GST) fusion protein ATF2 was ex-
pressed in Escherichia coli. The E. coli strain transformed with the
pGEX2-ATF2 plasmid was a gift from F. Porteu (INSERM U363,
Ho“pital Cochin, Paris, France). Overexpression of the protein was
induced with 1 mM isopropyl-L-D-thiogalactopyranoside. Then, cells
were pelleted, resuspended in ice-cold PBS (containing 1% Triton X-
100 and 1 mM PMSF) and lysed by sonication. The fusion protein
was isolated by adding glutathione-Sepharose beads to the lysate. The
GST-fusion protein was eluted from the beads by incubation with
20 mM reduced glutathione in 100 mM Tris^HCl pH 8 containing
100 mM NaCl, 1 mM PMSF and 2 mM dithiothreitol (DTT).
2.7. In vitro protein kinase activity
The cell lysates obtained as described above were immunoprecipi-
tated with p38 MAP kinase antibodies and protein G-Sepharose
beads. After rocking 2 h at 4‡C, the beads were washed extensively
with lysis bu¡er containing 1 mM Na2VO4 and once with kinase
bu¡er (25 mM HEPES pH 7.4, 25 mM MgCl2, 2 mM DTT, 0.5
mM Na2VO4, 25 mM glycerophosphate and 25 mM ATP). Then,
immunoprecipitates were incubated with 40 Wl kinase bu¡er contain-
ing 5 Wg ATF2 and 10 WCi [Q-32P]ATP for 30 min at 30‡C. The
reaction was stopped by addition of Laemmli sample bu¡er. The
samples were analyzed by 10% SDS^PAGE and autoradiography.
3. Results
3.1. TIMP-1 promotes cell growth and erythroid di¡erentiation
Since TIMP-1 has been described to stimulate growth of a
wide range of cells, we studied TIMP-1 e¡ects on UT-7 cell
proliferation and erythroid di¡erentiation. Experiments were
realized in the absence of serum to rule out the e¡ect of
TIMP-1 present in serum. Addition of human recombinant
TIMP-1 in the medium signi¢cantly induced cells to di¡eren-
tiate (Fig. 1A) and grow (Fig. 1B). TIMP-1 e¡ect was dose-
dependent and reached a maximum at 5 and 10 ng/ml for
proliferation and di¡erentiation, respectively.
3.2. TIMP-1 induces tyrosine phosphorylation of intracellular
proteins
Little is known on signal transduction pathways induced by
TIMPs. To analyze the signaling of TIMP-1, we examined the
pattern of tyrosine-phosphorylated proteins after stimulation
for 5 min with various concentrations of TIMP-1. Fig. 2
showed that TIMP-1 induced tyrosine phosphorylation of sev-
eral proteins with molecular masses ranging from 36 to 212
kDa. The e¡ect of TIMP-1 was dose-dependent. Tyrosine
phosphorylation of proteins induced by TIMP-1 was e¡ective
as soon as 1 min, reached a maximum between 5 and 10 min
and returned to the basal level after 30 min (not shown).
3.3. TIMP-1 induces activation of the p38 MAP kinase but not
extracellular signal-regulated kinase (ERK) 1/2
We have demonstrated that TIMP-1 is able to promote
growth and di¡erentiation of UT-7 cells. So, we investigated
the possible involvement of the MAP kinases ERK1/2 and
p38 in TIMP-1 signaling. Cells were stimulated with various
concentrations of TIMP-1 and whole cell extracts were ana-
Fig. 1. E¡ect of TIMP-1 on UT-7 cell di¡erentiation and prolifera-
tion. Cells (0.5U106) were incubated with various concentrations of
TIMP-1 (0^100 ng/ml) for 2 days. A: Cell di¡erentiation was eval-
uated by benzidine staining and expressed as a percentage of hemo-
globinized cells. B: Cell proliferation was evaluated by trypan blue
exclusion and expressed as a percent of control without TIMP-1
(100% = 0.5U106). The results were the means þ S.E.M. from three
separate experiments.
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lyzed by Western blotting using speci¢c antibodies which rec-
ognized the phosphorylated form of the MAP kinases. Any
concentration of TIMP-1 used induced the phosphorylation
of the kinases ERK1/2 whereas Epo did (Fig. 3). On the other
hand, TIMP-1 (25 ng/ml) induced the phosphorylation of the
p38 MAP kinase as soon as 1 min with a maximal e¡ect
between 5 and 10 min (Fig. 4A). This TIMP-1 concentration
was shown to induce UT-7 cell di¡erentiation. In parallel, the
p38 kinase activity assay with GST-ATF2 as a substrate
showed that TIMP-1 rapidly and transiently increased the
p38 activity (Fig. 4B). The maximal activity was observed at
5^10 min. Furthermore, the TIMP-1-induced phosphorylation
of the p38 as well as the p38 kinase activity is completely
inhibited by SB203580, a speci¢c inhibitor of the p38 MAP
kinase (Fig. 4C).
3.4. SB203580 inhibits TIMP-1-induced UT-7 cell
di¡erentiation
To evaluate the role of the p38 MAP kinase pathway dur-
ing growth and/or di¡erentiation induced by TIMP-1, cells
were incubated with TIMP-1 in the presence or the absence
of 5 WM SB203580. Proliferation and erythroid di¡erentiation
were measured as described in Section 2.2. Fig. 5 showed that
SB203580 reduced of 47% and 60% erythroid di¡erentiation
induced by 5 and 10 ng/ml TIMP-1, respectively, but had no
e¡ect on cell proliferation (not shown). This result indicated
that the p38 MAP kinase pathway was involved in TIMP-1-
induced erythroid di¡erentiation.
Fig. 2. Tyrosine phosphorylation induced by TIMP-1. Cells
(0.5U106) were stimulated for 5 min with various concentrations of
TIMP-1 (0^100 ng/ml). Whole cell extracts were analyzed by SDS^
PAGE and Western blotting using anti-phosphotyrosine antibodies.
Fig. 3. E¡ect of TIMP-1 on the phosphorylation of ERK1/2. Cells
(1U106) were stimulated with various concentrations of TIMP-1
(0^25 ng/ml). Whole cell extracts were analyzed by SDS^PAGE and
Western blotting using antibodies which recognized the phosphory-
lated form of the MAP kinases p42p44 (p-p42, p-p44). The same
protein samples were reprobed with anti-p42p44 antibodies.
Fig. 4. Activation of the p38 MAP kinase by TIMP-1. Cells were
stimulated for various times with 25 ng/ml TIMP-1. A: Whole cells
extracts (1U106) were analyzed by SDS^PAGE and Western blot-
ting using speci¢c antibodies which recognized the phosphorylated
form of the p38 (p-p38). The same protein samples were reprobed
with anti-p38 antibodies. B: Cell lysates (10U106) were immunopre-
cipitated with anti-p38 antibodies and the p38 kinase activity was
measured using GST-ATF2 as a substrate (as described in Section
2). C: Cells were preincubated for 20 min with 5 WM SB203580, left
untreated (C) or stimulated for 5 min with 25 ng/ml TIMP-1. Phos-
phorylation of the p38 and p38 kinase activity was evaluated as de-
scribed above.
Fig. 5. E¡ect of SB203580 on UT-7 cell di¡erentiation induced by
TIMP-1. Cells (0.5U106) were incubated with 5 and 10 ng/ml
TIMP-1 in the presence (F) or the absence (E) of 5 WM SB203580
for 2 days. Erythroid di¡erentiation was evaluated by benzidine
staining. Results are expressed as a percentage of hemoglobinized
cells and are the means þ S.E.M. of three separate experiments.
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3.5. TIMP-1 induces phosphorylation of JNK1/2
We further examined the e¡ect of TIMP-1 on JNK1/2
phosphorylation. After cell stimulation for various times
with 25 ng/ml TIMP-1, whole cell extracts were analyzed by
SDS^PAGE and Western blotting using speci¢c antibodies
which recognize the phosphorylated form of JNK1/2. As
shown in Fig. 6A, TIMP-1 induced a rapid and transient
phosphorylation of the two isoforms of JNK. The JNK phos-
phorylation was observed as soon as 1 min and returned to
the basal level after 10 min. The TIMP-1-induced phosphor-
ylation of JNK1/2 was not inhibited by 5 WM SB203580 (Fig.
6B).
4. Discussion
TIMPs are multifunctional proteins with pleiotropic e¡ects.
Although most of the literature pertains to their metallopro-
teinases inhibitory function, TIMPs and more particularly
TIMP-1 and TIMP-2 have been described as being growth-
modulating factors. We report here that TIMP-1 alone in-
duces growth and erythroid di¡erentiation of UT-7 cells in
a dose-dependent manner. Our results are consistent with
others previous reports which demonstrated EPA and cell
growth promoting activity for TIMP-1. TIMP-1 stimulated
both growth and di¡erentiation of erythroid progenitor cells
[11] and human erythroleukemia cell line K562 [4]. TIMP-1
also induced di¡erentiation of the Epo-responsive mouse
erythroleukemia cell line ELM-I-1-3 [12]. Moreover, TIMP-1
has been described to be mitogenic for a broad range of hu-
man and bovine cells including ¢broblasts and keratinocytes
[2,6] and the mitogenic activity of TIMP-1 is independent of
its metalloproteinase inhibitory activity [13].
Up to date there is little information on intracellular signal-
ing of TIMPs. Our results show that many intracellular pro-
teins are phosphorylated after UT-7 cell stimulation with
TIMP-1. The decrease of the phosphorylation observed after
30 min of stimulation is correlated with the kinetics of tyro-
sine phosphorylation of intracellular proteins and probably
corresponds to the termination of TIMP-1 signaling. Similar
results were previously described in the human osteosarcoma
cell line MG-63 [7]. The signaling of TIMPs was thought to be
a direct cellular e¡ect probably mediated by a cell surface
receptor. Previous reports evidenced the presence of both
high and low a⁄nity binding sites for TIMP-2 on the cell
surface of Raji cells [6] and for TIMP-1 on K562 cells and
keratinocytes [4,14]. Recently, it was reported that BC-61 cells
expressed a transmembrane protein of 80 kDa able to bind
TIMP-1 with a high a⁄nity [15] but TIMP-1 receptor has not
yet been cloned. TIMP-1 does not induce tyrosine phosphor-
ylation of the Epo receptor (not shown) so suggesting that
TIMP-1 signaling is independent of the Epo receptor.
As Epo signaling involves the MAP kinase pathways and
biological activity of TIMP-1 was ¢rstly described as an EPA,
we investigated the role of the MAP kinases in TIMP-1 signal-
ing. The MAP kinases ERK1/2 are not phosphorylated after
UT-7 cell stimulation with either growth or di¡erentiation
promoting concentrations of TIMP-1 and our results are
somewhat di¡erent from a previous study in the osteosarcoma
cell line MG-63 [7]. In UT-7 cells, Epo-induced activation of
ERKs was described to be correlated with cell proliferation
[16] and recent studies indicated that activation of ERKs was
essential for Epo-induced SKT-6 cell growth but not for Epo-
induced erythroid di¡erentiation [17]. ERKs are activated by
various cell growth and di¡erentiation stimuli [18] and these
results suggest that the precise role of the MAP kinases
ERK1/2 in cell di¡erentiation and/or proliferation is not de-
terminated.
We report here that UT-7 cell di¡erentiation induced by
TIMP-1 involves the p38 MAP kinase pathway. Indeed,
TIMP-1 induces the speci¢c phosphorylation of the p38 and
the time-course of phosphorylation closely paralleled its ki-
nase activity. Both p38 phosphorylation and p38 kinase activ-
ity are completely inhibited by SB203580, a speci¢c inhibitor
of the p38 MAP kinase. While this compound has been de-
scribed to inhibit the activity but not the phosphorylation of
the p38 MAP kinase, it has also been demonstrated that
SB203580 inhibited stimulus-induced activating phosphoryla-
tion of the p38 at the Thr-Gly-Tyr activation motif leading to
the inhibition of the p38 kinase activity [19]. Moreover, we
show that SB203580 signi¢cantly inhibits UT-7 cell di¡eren-
tiation induced by TIMP-1. Activation of the p38 MAP ki-
nase has also been evidenced to be required for Epo-induced
SKT-6 cell di¡erentiation but not for proliferation [20] and
both expression and phosphorylation of the heat shock pro-
tein hsp 28, a target of the p38, are correlated with hemin-
induced K562 cell di¡erentiation [20].
We also show that TIMP-1 induces the phosphorylation of
JNK1/2 which was not inhibited by SB203580. JNKs have
been described as essential for cell di¡erentiation in several
cell lines [21,22]. Nevertheless, a de¢nitive role for the kinases
Fig. 6. Activation of JNK1/2 by TIMP-1. A: Cells (1U106) were
stimulated for various times with 25 ng/ml TIMP-1. B: Cells
(1U106) were stimulated for 2 min with 25 ng/ml TIMP-1 in the
presence or absence of 5 WM SB203580. Whole cell extracts were
analyzed by SDS^PAGE and Western blotting using speci¢c anti-
bodies which recognized the phosphorylated form of JNK1/2
(p-JNK1 and p-JNK2). The same protein samples were reprobed
with anti-JNK1/2 antibodies.
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p38 and JNK is not clearly established and these kinases
appear to be involved in opposite e¡ects. Indeed, in the mur-
ine erythroid progenitor cell line HCD-57, sustained activa-
tion of p38/JNK is observed after Epo withdrawal leading to
cell apoptosis whereas in SKT-6 cells and FD-Epo cells, acti-
vation of p38/JNK is induced during Epo-induced di¡erentia-
tion and proliferation, respectively [17,21]. Our results show
that TIMP-1 induces activation of the MAP kinases p38 and
JNK while ERK1/2 are not phosphorylated after stimulation
with TIMP-1. This dynamic balance between ERK and JNK/
p38 pathways has been demonstrated as being important in
determining the cell fate, whether cell undergoes proliferation,
di¡erentiation or apoptosis [23,24].
The present study suggests that TIMP-1 promotes UT-7 cell
proliferation and erythroid di¡erentiation. Moreover, TIMP-1
induces the tyrosine phosphorylation of a number of intra-
cellular proteins and TIMP-1-induced erythroid di¡erentia-
tion requires the p38 MAP kinase pathway. Further experi-
ments will be required to identify the upstream regulators of
the p38 MAP kinase in TIMP-1 signaling.
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